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ABSTRACT The synthesis, uptake, and pro-
cessing of yolk proteins remain poorly described
aspects of oviparous reproductive development. In this
study, we report the identification and characterization
of two protease inhibitors in rainbow trout ovary whose
expression and distribution are directly associated with
yolk protein uptake in vitellogenic oocytes. The first
transcript, termed ‘‘oocyte protease inhibitor-1’’ (OPI-1),
is predicted to encode a 9.1 kDa, 87 amino acid
protein containing a single thyroglobulin type-1 (TY)
domain, identifying it as a putative TY domain inhibitor.
The second transcript, termed OPI-2, is predicted to
encode an 18.3 kDa, 173 amino acid protein with two
similar, but not identical, TY domains. Messenger RNA
expression of both genes was first detected in ovarian
tissues at the onset of vitellogenesis, and persisted
throughout the vitellogenic growth phase. We did not
detect expression of either gene in previtellogenic
ovaries, nor in any somatic tissues examined. Expres-
sion of OPI-1 mRNA was significantly reduced in
atretic follicles as compared to healthy vitellogenic
follicles, suggesting a downregulation of inhibitor
expression during oocyte atresia. Western immunoblot
analyses of whole yolk from vitellogenic oocytes
revealed the presence of two immunoreactive proteins
that corresponded to the predicted sizes of OPI-1 and
OPI-2. We detected strong crossreactivity of this anti-
serum with specific vesicles in the cortical ooplasm of
vitellogenic oocytes, in regions directly associated with
vitellogenin processing. The identification of OPI-1 and
OPI-2 provides new evidence for the expression of
multiple TY domain protease inhibitors likely involved
in the regulation of yolk processing during oocyte
growth in salmonids. Mol. Reprod. Dev. 69: 205–
214, 2004.  2004 Wiley-Liss, Inc.
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INTRODUCTION
In oviparous vertebrates, oocyte growth is dependent
upon the coordinated synthesis, uptake, processing, and
storage of yolk proteins, derived primarily from the
hepatic precursor vitellogenin. This suite of biochemical
processes, collectively known as vitellogenesis, is essen-
tial for the production of oocytes with sufficient yolk
reserves to metabolically sustain the initial phases of
embryonic and larval growth (Tata and Smith, 1979;
Valle, 1993). Understanding the physiological and
biochemical regulation of vitellogenesis thus remains a
theme of considerable interest among reproductive
biologists.
Much of what we currently know about vitellogenesis
in vertebrates derives from studies in teleost fishes
(Tyler and Sumpter, 1996). In teleosts, as in other
vertebrates, vitellogenin is synthesized by the liver
under estrogenic stimulation, secreted into the general
circulation, and sequestered by developing oocytes
via receptor-mediated endocytosis (Tyler et al., 1990,
1991). Subsequent intraoocytic proteolysis of vitello-
genin generates an assortment of vesicular lipoproteins,
(e.g., lipovitellins); these coalesce to form yolk platelets
that are stored in the oocyte for the duration of oocyte
development (Wallace and Selman, 1985; Carnevali
et al., 1999a,b). After ovulation and fertilization, latent
endogenous proteases are activated to initiate hydro-
lysis of the yolk platelets; the resultant release of lipids
and free amino acids provides metabolic substrate for
embryonic growth (Krieger and Fleig, 1999; Carnevali
et al., 1999a; Hiramatsu et al., 2002).
There is considerable evidence to suggest that the
proteolytic processing of both vitellogenin and yolk
platelets is mediated by cathepsins, a diverse family of
serine, aspartate, and cysteine proteases. Cathepsins
have been implicated in yolk processing in fishes
(Kestemont et al., 1999; Carnevali et al., 1999a,b;
Kwon et al., 2001; Hiramatsu et al., 2002; Wood and
Van Der Kraak, 2003), amphibians (Yoshizaki and
Yonezawa, 1996), reptiles (De Stasio et al., 1999), birds
(Gerhartz et al., 1999), and insects (Yamamoto et al.,
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1994; Ribolla et al., 2001), suggesting an evolutionarily
conserved role for these enzymes in vitellogenin and
yolk processing.
Despite evidence invoking cathepsins as modulators
of yolk processing, there is little available information on
the mechanisms by which these enzymes are regulated.
Conventional protease inhibitors (e.g., cystatins) have
been characterized in ovarian tissues (Coffman and
Goetz, 1998; Li et al., 1998; Curry and Wheeler, 2002),
but to our knowledge, nonehas been shown to be directly
involved in regulating yolk proteolysis. However, the
recent identification of ‘‘egg cysteine protease inhibitor’’
(ECI) in chum salmon provided new evidence for the
existence of oocyte-specific protease inhibitors in fish
(Yamashita and Konagaya, 1991). Chum salmon ECI
(purified from ovulated eggs) exhibited inhibitory
activity against cathepsins and cathepsin-like cysteine
proteases in vitro, but was structurally unrelated to
conventional cysteine protease inhibitors (Yamashita
and Konagaya, 1991, 1996).
The defining feature of ECI is a cysteine-rich thyro-
globulin type-1 (TY) domain, characteristic of a protein
group recently termed ‘‘thyroglobulin type-1 domain
protease inhibitors’’ (Molina et al., 1996; Lenarcic et al.,
1997). A cDNA encoding a putatively homologous TY
domain inhibitor (oocyte cysteine protease inhibitor,
OCPI) was recently cloned from brook trout ovarian
tissues (Bobe and Goetz, 2001), and shown to exhibit
ovary-specific expression. These expression data, how-
ever, were derived almost exclusively from periovula-
tory ovarian tissues, thus there is no information on the
expression of this gene during the prolonged vitellogenic
phase of oocyte development, during which the specific
regulation of oocyte proteases is required for proper
oocyte development.
The ability of chum salmon ECI to inhibit cathepsins
(Yamashita and Konagaya, 1991), and recent studies
demonstrating regulated expression of cathepsins and
other proteases in developing and degenerating teleost
oocytes (Kestemont et al., 1999; Carnevali et al., 1999a;
Kwon et al., 2001; Wood and Van Der Kraak, 2003), led
us to hypothesize that ovarian TY domain inhibitors
function to regulate yolk processing enzymes during
vitellogenic oocyte development. We sought to test this
hypothesis by cloning the homolog of ECI in rainbow
trout, and characterizing its expression throughout
vitellogenic oocyte development. We predicted that the
expression of this putative TY domain inhibitor would
temporally and spatially correlate with yolk protein
deposition in vitellogenic oocytes. Furthermore, we
predicted a downregulation of its expression in degen-
erating (atretic) oocytes, in which a detectable increase
in cathepsin-like enzyme activities has recently been
demonstrated (Kestemont et al., 1999; Wood and Van
Der Kraak, 2003). These efforts led to the fortuitous
identification of a second cDNA encoding a novel TY
domain inhibitor that resembles of tandem duplication
of the original target gene. Herein, we use RT-PCR and
immunocytochemistry to describe the temporal and
spatial expression patterns of these putatively para-




Oligonucleotide primers, SuperScriptTM II reverse
transcriptase, GeneRacerTM reagents, and RNase H
were purchased from Invitrogen (Carlsbad, CA). Ran-
dom hexamer primers were from Promega (Madison,
WI). PCR nucleotide mix (dNTPs), dithiothreitol (DTT),
first strand synthesis buffer (5X RT buffer), PCR reac-
tion buffer (10 PCR buffer), and TAq DNA polymerase
(5 U/ml) were from Roche Molecular Biochemicals
(Laval, PQ). RNase inhibitor (RNAguardTM, 25 U/ml)
and ECL reagents were from Amersham (Baie d’Urfé,
PQ). Polyclonal rabbit antiserum raised against mal-
tose-binding protein (anti-MBP) was purchased from
New England BioLabs (Beverly, MA). Cy3-conjugated
anti-rabbit IgG was purchased from Chemicon Interna-
tional (Temecula, CA). Unless specified otherwise, all
other reagents were purchased from Sigma or Fisher.
Water used for RNA procedures was double-distilled,
pretreated with diethylpyrocarbonate (DEPC), and
autoclaved.
Experimental Animals
Adult rainbow trout were acquired from the Uni-
versity of Guelph Aquaculture Research Station (Alma,
ON). These fishwere derived from a fall-spawning stock
and were raised to adulthood in outdoor tanks receiving
spring water at ambient temperatures. The fish were
transferred to the Hagen Aqualab at the University of
Guelph, where they were maintained indoors under a
simulated natural photoperiod in circular fiberglass
tanks receiving re-circulated well water (9 18C).
The fish were fed to satiety 3–4 times per week with a
commercial trout formulation (Martin Mills, Elmira,
ON). All experiments were conducted in accordance
with animal use protocols approved by the Canadian
Council for Animal Care.
Tissue Sampling
Ovarian tissues were collected from twelve female
fish over the course of a spawning season. Three fish
were sampled during the previtellogenic phase
(follicle diameter (FD) <0.1 mm); three fish had early-
vitellogenic ovaries (FD 0.5–1 mm); four fish had
mid-vitellogenic ovaries (FD, 2–3 mm), and two fish
had ovaries in advanced stages of vitellogenesis (FD, 3–
4 mm).
The fish were anaesthetized with 2-phenoxyethanol
and quickly killed by cervical transection. A subsample
of ovarian tissue (follicles and stroma) was immediately
frozen in liquid nitrogen, and another subsample was
fixed in 4% phosphate-buffered paraformaldehyde for
immunocytochemical analysis. Selected somatic tissues
were also excised and frozen in liquid nitrogen; these
included liver, kidney, heart, spleen, white muscle,
brain, intestine, gill, and ovary. Additionally, from a
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subset of vitellogenic fish, we isolated and snap-froze
selected follicles that displayed morphological features
indicative of atresia (collapsed follicular wall, increased
vascularization).
RNA Extraction
Total RNA was extracted from ovarian tissue homo-
genates using Trizol Reagent, according to supplier’s
instructions. Purified total RNA was resuspended in an
appropriate volume of sterile, DEPC-treated water, and
quantified by absorbance at 260 nm.
First-Strand Synthesis (for RT-PCR)
Aliquots of total RNA (500 ng) from individual tissues
were combinedwith0.1ngof randomhexamersprimers,
brought to a final volume of 12 ml in DEPC-treated
water, incubated for 5 min at 708C, and transferred to
ice. The volume of each reaction mixture was brought
to 25 ml by the addition of (concentrations/activities
represent final values): 5 RT buffer (50 mM Tris-HCl,
75 mM KCl, 3 mM MgCl2), DTT (10 mM), dNTPs
(0.5 mM), RNase inhibitor (25 U), Moloney murine
leukemia virus reverse transcriptase (200 U), and
DEPC-treated ddH2O. Samples were incubated for 1 hr
at 378C, followed by 5min at 908C to inactive the reverse
transcriptase. Reaction products were stored at 208C
until PCR amplification. To confirm the absence of
genomic DNA contamination, equivalent RNA samples
from each tissue were treated in parallel to similar
reaction conditions, but without the addition of the
reverse transcriptase enzyme.
PCR Amplification
For initial amplification of the target gene (termed
‘‘oocyte protease inhibitor-1,’’ OPI-1), we designed an
oligonucleotide primer pair (RT-OPI-F1, RT-OPI-R1;
Table 1) that flanked a 281 base-pair (bp) region
(positions 29 to 310) of the full-length cDNA sequence
of brook trout OCPI (Accession no. AF223387). For
subsequent amplification of a cDNA spanning the com-
plete open reading frame, a second antisense primer
(RT-OPI-R2)wasdesigned, downstreamof thepredicted
stop codon.
Each PCR reaction tube contained 12.5 ml of first-
strand cDNA, PCR nucleotide mix (0.2 mM), primers
(0.4 mm each), PCR reaction buffer (10 mM Tris-HCl,
50 mM KCl, 1.5 mM MgCl2), and TAq polymerase
(2.5 U), diluted in sterile ddH2O to a volume of 100 ml.
An initial denaturing step (948C, 10 min) was followed
by 35 cycles in the following conditions: denaturation
(948C for 1 min), annealing (608C for 1 min), and exten-
sion (728C for 1 min), in an Eppendorf Mastercycler1
gradient thermocycler. After a terminal extension of
5 min at 728C, the reaction products were stored at
208C.
To confirm the presence and integrity of RNA in each
preparation, we performed parallel PCR reactions using
oligonucleotide primers (Actin-F1, Actin-R1) for rain-
bow trout b-actin (Accession No. AJ438158). Reaction
conditions were identical to those described above.
PCR products were fractionated in 1.5% agarose gels,
stained with ethidium bromide, and visualized under
UV light. The molecular weights of amplification pro-
ducts were estimated by comparison to the migration
distance of DNA molecular weight standards.
30-Rapid Amplification of
cDNA Ends (RACE) PCR
The above PCR reactions led to the identification of
two cDNA sequences (see Results). The longer of these
sequences contained an incomplete open reading frame,
so we employed 30-RACE PCR to further determine the
sequence of this cDNA.
Total RNA (500 ng) and GeneRacerTM Oligo dT
primers (0.1 ng) were diluted to 12 ml in sterile, DEPC-
treated water. Each tube was incubated for 5 min at
658C, transferred to ice, and the volume of each reaction
was brought to 20 ml by the addition of 5 RT Buffer
(50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl2), DTT
(10 mM), dNTPs (0.5 mM), RNase inhibitor (25 U),
SuperScriptTM II reverse-transcriptase (200 U) and
DEPC-treated ddH2O. Reaction tubes were incubated
for 1 hr at 428C, followed by 15 min at 708C. Samples
were then digested for 15 min at 378C with RNase H
(2 U), and the reaction products were stored at 208C.
The absence of genomic DNA contamination was con-
firmed as described above.
30-RACE PCR reaction mixtures contained 2 ml of
30-RACE cDNA, the GeneRacerTM 30 oligonucleotide
primer (supplied), a gene specific primer (RT-OPI-2-F1),
and reagents as specified in themanufacturer’s instruc-
tions (GeneRacerTM Kit). PCR cycle conditions were
identical to those described above.
Cloning and Sequencing
Where possible, PCR products were directly sequenc-
ed by the terminal dye-labeling method on an ABI
automated sequencer (Applied Biosystems, Foster City,
CA). Products were first purified using the QIAquick1
PCRPurification Kit (QIAGEN, Inc., Mississauga, ON),
and then sequenced in both directions using the primers
designed for their initial amplification. Sequences were
confirmed by sequencing reaction products from at least
three different fish. If direct sequencingwasnot possible
(i.e., multiple amplification products), then the desired
band was excised from the gel, purified (QIAquick1
Gel Extraction Kit, QIAGEN, Inc.), inserted into the
pCR12.1-TOPO1 vector (Invitrogen) and transfected
into competent TOP10 One Shot1 chemically com-
petent cells (Invitrogen). Recombinants were identified
TABLE 1. Oligonucleotide Primers Used in This Study
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through blue-white color selection, grown overnight at
378C in selective medium (LB broth with ampicillin,
50 mg/ml), and plasmid DNA was purified using the
QIAPrep1 Mini Plasmid Identification Kit (QIAGEN,
Inc.). Automated sequencing of individual clones was
performed using M13 sequencing primers.
Semi-Quantitative RT-PCR
Semi-quantitative RT-PCR was employed to test the
hypothesis that mRNA expression of OPI-1 is down-
regulated in atretic follicles as compared to healthy
vitellogenic follicles. First-strand synthesis, in 100 ml
volumes, was performed as described above, using total
RNA from either healthy mid-vitellogenic follicles, or
morphologically atretic follicles. PCR amplification of
OPI-1 was performed with the primer pair RT-OPI-F1
and RT-OPI-R2, and rainbow trout b-actin was used as
the reference standard. Reaction tubes containing equal
volumes of first-strand cDNA from each sample were
amplified for 12–36 PCR cycles (in 2–3 cycle incre-
ments), electrophoretically fractionated and stained
with ethidium bromide. PCR amplification products
were quantified densitometrically using digital imaging
software (IS-1000; Alpha Innotech Corp., San Leandro,
CA). The relative expression levels of OPI-1 in vitello-
genic andatretic follicleswere determinedby comparing
the ratio of the densities of OPI-1 and b-actin ampli-
fication products after an appropriate number of PCR
cycles, ensuring amplification of each target sequence
was terminated during the exponential phase of ampli-
fication; this was quantitatively determined, and shown
to be consistent between samples. Comparisons were
made after 18 cycles for b-actin, and 27 cycles for OPI-1,
and each reactionwas repeated three timeswith similar
results.
Western Immunoblotting
We used Western immunoblotting to visualize pro-
teins encoded by the PCR-amplified genes. Vitellogenic
ovarian follicles were punctured and samples of whole
yolk were diluted 1:100 in SDS–PAGE sample buffer
(1% SDS, 0.1 M Tris-HCl, 10% glycerol, 0.02% bromo-
phenol blue, 2% 2-mercaptoethanol), heated for 10 min
at 658C, electrophoretically separated on 14% polyacry-
lamide gels, and transferred for 30 min to Immobilon-P
PVDF membranes (Millipore, Milwaukee, WI). After
transfer, themembraneswere incubated for 2hr at room
temperature in blotting buffer (phosphate-buffered
saline, 0.1% Tween120, 3% BSA, pH 7.4), and then
blotted overnight at 48C with rabbit antiserum (1:1,000
in blotting buffer) raised against a recombinantly
expressed maltose-binding protein:brook trout OCPI
fusion protein (anti-OCPI) (Bobe and Goetz, 2001),
generously provided by Dr. Frederick W. Goetz (Marine
Biological Laboratories, Wood’s Hole, MA). Membranes
were then blotted for 2 hr at room temperature with
secondary antibody (HRP-conjugated goat anti-rabbit
IgG, 1:5,000 in blotting buffer) and immunoreactive
proteins were visualized using the ECL detection
system. Negative controls were performed by immuno-
blotting with rabbit antiserum (1:1,000) raised against
maltose-binding protein (anti-MBP).
Immunocytochemistry
Immunocytochemistry was used to determine the
spatial expression patterns of target proteins in situ.
Paraformaldehyde-fixed ovarian tissues were dehy-
drated in a graded ethanol series, embedded in paraffin,
and sectioned at 4 mm. After deparaffinizing (1 hr at
608C), the sections were cleared in xylenes, rehydrated
in a graded ethanol series, and washed three times in
phosphate-buffered saline containing 0.1% Tween 20
(PBST, pH7.4). Sectionswere thenpreincubated for 2hr
at room temperature in blocking buffer (0.2% BSA, 2%
goat serum, 1%DMSO, in PBST), followed by overnight
(48C) incubation in primary antiserum (anti-OCPI,
diluted 1:1,000 in blocking buffer). Two control groups
were included: (1) a subset of slides were incubated with
control antibody (anti-MBP, 1:1,000); and (2) a subset
of slides were incubated in blocking buffer without
primary antibody. All slides were then washed 3
10 min in PBST, and incubated for 2 hr at room tem-
perature in secondary antibody (Cy3-conjugated anti-
rabbit IgG; 1:500 in blocking buffer). The sections
were then washed (310 min in PBST) and examined
under fluorescence and differential interference con-
trast microscopy. Digital images were captured using
Scion Image software (National Institutes of Health,
Bethesda, MA).
Data Analyses
Cloned sequences were submitted to public data-
base searches (BLAST) to identify similar published
sequences. Multiple sequence alignments were gener-
ated using ClustalW, and protein sequence analyses
were performed with the Sequence Manipulation
Suite (http://www.bioinformatics.org/SMS/), the Simple
Modular Architecture Research Tool (Letunic et al.,
2002) and Pfam (http://pfam.wustl.edu/). The relative
mRNA expression levels of OPI-1 mRNA in healthy
vitellogenic and atretic follicles were statistically com-
pared using an unpaired Student’s t-test. Differences
were judged to be significant if P<0.05.
RESULTS
Sequence Identification
RT-PCR of total RNA from rainbow trout mid-
vitellogenic ovaries using the primer pair RT-OPI-F1
and RT-OPI-R1 yielded a single 279-bp cDNA (Fig. 1,
lane 2). This sequence showed high (94%) identity to
brook trout OCPI, confirming that we had successfully
amplified the target sequence. This sequence contained
an ATG site at position 28, flanked by the Kozak
initiation sequence (ACCATGG) (Kozak, 1986), but did
not contain an in-frame stop codon. RT-PCR of total
RNA from rainbow trout mid-vitellogenic ovaries using
the primer pair RT-OPI-F1 and RT-OPI-R2 yielded a
single 330-bp cDNA (Fig. 1, lane 3). This sequence
was identical to the initial transcript in corresponding
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regions, and contained an in-frame stop codon (TAG) at
position 289.
RT-PCR of total RNA from early-vitellogenic ovarian
tissues, using either primer pair, frequently yielded two
amplification products. Using the second primer pair
(RT-OPI-F1 and RT-OPI-R2), these amplicons were ap-
proximately 330 and 550 bp (Fig. 1, lane 4). The shorter
amplicon was identical in sequence to the 330 bp cDNA
previously identified; the longer sequence was revealed
to be a partial cDNA that resembled a tandem dupli-
cation of the shorter cDNA, but which did not contain
an in-frame stop codon. 30-RACE PCR, using the
GeneRacer 30 primer and a gene-specific primer
(RT-OPI-2-F1), using total RNA purified from mid-
and late-vitellogenic ovarian tissues, generated a 420 bp
cDNA, which was subsequently cloned and sequenced.
The assembled sequence (645 bp) contained an in-
frame stop codon at position 547, and a polyadenylation
signal.
Sequence Analysis and Tissue Localization
The open reading frame (nucleotides 28–288) of the
shorter (330 bp) cDNA is predicted to encode an 87
amino acid peptide (Fig. 2), with a calculated molecular
mass of 9.1 kDa. The deduced amino acid sequence has
high identity to chum salmon ECI-3, and the deduced
amino acid sequences of brook trout OCPI and Atlantic
salmon cys protease inhibitor (Table 2). The rainbow
trout sequence contains a single TY motif, spanning
residues 27–87 (Fig. 3a) (Marchler-Bauer et al., 2002).
Based on the presence of this single TY motif, we have
termed this cDNA sequence ‘‘oocyte protease inhibitor-
1’’ (OPI-1, GenBank Accession No. AY094359).
Using the initial primer pair (RT-OPI-F1, RT-OPI-
R1), we amplified OPI-1 from early-, mid-, and late-
vitellogenic ovarian tissues, but were unable to amplify
OPI-1 from liver, kidney, spleen, brain, muscle, gill, or
heart (Fig. 4, upper panel). We were also unable to
amplify OPI-1 using total RNA purified from previtello-
genic ovarian tissues (n¼ 3 fishes; Fig. 4, upper panel).
b-actin was abundantly amplified from each sample,
confirming the presence and integrity of first-strand
cDNA in each tissue (Fig. 4, bottom panel).
The open reading frame (nucleotides 28–546) of the
longer (645 bp) cDNA is predicted to encode a 173 amino
acid peptide (Fig. 5), containing two TY domains
spanning residues 27–88 and 101–162, respectively
(Fig. 3a). These domains are similar but not identical,
and neither domain is identical to the TY domain in
OPI-1 (Fig. 3b). Based on the presence of these two TY
domains, we have named this sequence ‘‘oocyte protease
inhibitor-2’’ (OPI-2; Accession No. AF529226).
TABLE 2. Comparison of Rainbow Trout OPI-1 (AY094359) Amino Acid
Sequence With Putative Homologs Identified in Atlantic Salmon,
Brook Trout, and Chum Salmon
Gene name Accession no. Identity (%) Similarity (%)
Atlantic salmon cys protease
inhibitor
BE518516 97a 99a
Atlantic salmon cys protease
inhibitor
BE518515 72a 83a
Brook trout oocyte cysteine
protease inhibitor (OCPI)
AF223387 88a 92a
Chum salmon egg cysteine
protease inhibitor (ECI-1)
2207269A 63 84
aAmino acid sequences predicted from nucleotide sequence.
Fig. 1. Reverse transcription-polymerase chain reaction (RT-PCR)
products amplified from total RNA of rainbow trout vitellogenic
oocytes. Lane 1, molecular weight standard; lane 2, rainbow trout
OPI-1 partial cDNA (279 bp; amplified using RT-OPI-F1 and RT-OPI-
R1); lane 3, rainbow trout OPI-1 cDNA (330 bp; amplified using RT-
OPI-F1 and RT-OPI-R2); lane 4, OPI-2 partial cDNA (upper band, 548
bp; amplified using RT-OPI-F1 and RT-OPI-R2); lane 5, negative
control (no first-strand cDNA).
Fig. 2. Rainbow trout OPI-1 (Accession No. AY094359) cDNA
sequence, with translation to OPI-1 protein. Start and stop codons
are indicated with bold-faced text; putative thyroglobulin type-1
domain is indicated with shaded text.
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The initial RT-PCR reactions confirmed that OPI-2
mRNA is expressed in the early vitellogenic ovary, and
the gene-specific RACE-PCR results revealed expres-
sion of this transcript in mid- and late-vitellogenic
ovaries. Furthermore, since our initial primer pairs
(e.g., RT-OPI-F1, RT-OPI-R2) were shown to effectively
amplify OPI-2 if present, our results demonstrate that
OPI-2 mRNA is not detectably expressed in the pre-
vitellogenic ovary, or in any of the somatic tissues
examined (Fig. 4).
Immunoblotting
Western immunoblots of ooplasm from vitellogenic
oocytes using antiserum raised against brook trout
OCPI revealed two immunopositive bands, of approxi-
mately 10 and 22 kDA (Fig. 6). These bands are similar
in size to the predicted molecular weights of rainbow
trout OPI-1 (9.1 kDa) and OPI-2 (18.3 kDa). Immuno-
positive bands were not observed on blots using anti-
MBP as the primary antibody (Fig. 6).
Immunocytochemistry
Immunocytochemical analyses of rainbow trout ovar-
ian tissue sections using antiserum raised against brook
troutOCPI revealed intense immunostaining in vesicles
located in the cortical ooplasm of vitellogenic oocytes
(Fig. 7a,b). These vesicles were distinct from the yolk
vesicles that coalesce to form the yolk platelets. Since
our Western immunoblot results suggest that this
polyclonal antiserum crossreacts with both OPI-1 and
OPI-2, it is likely that the positive immunocytochemical
staining in these sections represents both proteins.
Epitope-specific antibodies are not currently available
for these proteins, preventing us from independently
determining the subcellular localization of each protein.
Fig. 3. A: Schematic diagram indicating the cysteine-rich thyroglobulin type-1 (TY) motifs in rainbow
trout OPI-1 and OPI-2. Corresponding amino acid residues are indicated in parentheses. B: ClustalW
alignments of thyroglobulin type-1 domains in rainbow trout OPI-1 and OPI-2. Asterisks denote the
location of domain-specific cysteine residues.
Fig. 4. Tissue distribution of rainbow trout OPI-1 (upper panel)
and b-actin cDNA (lower panel) as determined by reverse-transcrip-
tase polymerase chain reaction (RT-PCR). Each lane represents cDNA
amplified from 250 ng of total RNA from (2) mid-vitellogenic oocytes,
(3) brain, (4) kidney, (5) heart, (6) spleen, (7) white muscle, (8) liver,
(9) gill, (10) previtellogenic ovary, and (11) follicular epithelium.Lane1
(upper panel) contains a DNAmolecular weight standard and lane 12
(both panels) contains negative controls (no cDNA template).
Fig. 5. Rainbow trout OPI-2 (Accession no. AF529226) cDNA
sequence, with translation to OPI-2 protein. Start and stop codons
are indicated with bold-faced text; putative thyroglobulin type-1
domains are indicated with shaded text.
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We did not detect any positive immunostaining in
previtellogenic oocytes, nor did we detect any positive
immunostaining in somatic ovarian tissues (Fig. 7a,b).
Furthermore, no positive immunostaining was detected
in tissue sections incubated with secondary antibody
alone (results not shown). In some tissue sections, we
detected faint crossreactivity of the control antiserum
(anti-MBP) with ovarian vascular tissues (Fig. 7c,d); we
did not, however, detect any positive immunostaining
that corresponded to the positive immunostaining
detected with OCPI antiserum.
OPI-1 mRNA Expression in
Vitellogenic Versus Atretic Follicles
The amplification profile of b-actin with increasing
PCR cycle numbers (12–27) was consistent between
healthy and atretic oocytes (data not shown), confirming
that b-actin was an appropriate internal standard by
which to determine the relative expression of OPI-1.
Using this approach, we determined that OPI-1 mRNA
expression was significantly lower in atretic oocytes
as compared to healthy oocytes (t-test, P< 0.001, n¼3
(Fig. 8).
DISCUSSION
In this study, we report the identification and char-
acterization of two oocyte protease inhibitor cDNAs in
rainbow trout ovary. One of these cDNAs (OPI-1) is
predicted to encode the rainbow trout homolog of anOPI
recently identified in related teleosts (Yamashita and
Konagaya, 1996; Bobe and Goetz, 2001; Davey et al.,
2001). The second cDNA (OPI-2) is a novel gene that
resembles a tandem duplication of OPI-1, but which has
not previously been reported. Herein, we provide the
first datadescribing the temporal and spatial expression
profiles of bothgenes throughout thevitellogenic growth
phase of oocyte development. As hypothesized, these
genes were shown to be expressed exclusively during
vitellogenesis, in subcellular regions directly associated
with the uptake and processing of yolk lipoproteins (Sire
et al., 1994).
Both cDNAs contain at least one TY domain, encoding
a functional motif suggested to be the hallmark of a
novel class of protease inhibitors called ‘‘thyroglobulin
type-1 domain inhibitors’’ (Lenarcic and Turk, 1999).
Fig. 6. Western immunoblots of rainbow trout yolk/ooplasm using
(A) antiserum raised against brook trout OCPI (anti-OCPI), or (B)
antiserum raised against maltose-binding protein (anti-MBP).
No positive immunostaining was detected with anti-MBP (control
antibody).
Fig. 7. Fluorescence (A, C) and differential interference contrast
(B, D) microscopy images of rainbow trout ovarian sections immuno-
cytochemically stained with antiserum raised against (A) brook trout
OCPI (anti-OCPI), or (C) maltose-binding protein (anti-MBP). Positive
immunostaining for rainbow trout OPI(s) (A) is detected in vesicles in
the cortical ooplasm (arrows), but is not detected in yolk spheres
(asterisks), previtellogenic oocytes (PV), stromal tissue (ST), or the
somatic follicular epithelium (F). Weak crossreactivity of anti-MBP
(control) antiserum was detected in the ovarian vasculature (arrow-
head), but no positive immunostaining was detected in the ooplasm.
Scale bars indicate 100 mm.
Fig. 8. Relative mRNA expression of rainbow trout OPI-1 in
vitellogenic versus atretic oocytes. Values represent the meanSEM
of the ratios of OPI-1 expression to b-actin expression as determined by
semi-quantitative RT-PCR. Asterisk indicates a statistically signifi-
cant difference in relative OPI-1 expression between vitellogenic and
atretic oocytes (P< 0.05).
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This motif is found, often in repeats, among a variety
of different proteins, including thyroglobulin (11 TY
repeats), nidogen (2 TY repeats), sea anemone equista-
tin (3TYrepeats), bullfrog saxiphilin (2TYrepeats), and
all insulin-like growth factor binding proteins (1 TY
repeat each). While these proteins do not all function
exclusively as protease inhibitors, the presence of this
domain has been shown to confer resistance against
endogenous proteases, particularly cathepsins and
cathepsin-like proteases (Yamashita and Konagaya,
1991, 1996; Fowlkes et al., 1997; Lenarcic et al., 1997;
Lenarcic and Turk, 1999).
Multiple studies have identified cathepsin proteases
as key mediators of yolk processing during vitellogenic
oocyte development in awide variety of species (Fagotto,
1990; Nakamura et al., 1996; De Stasio et al., 1999;
Gerhartz et al., 1999; Carnevali et al., 1999b). What
remains enigmatic are the mechanisms by which multi-
ple cathepsin proteases are differentially controlled
during key developmental events involving proteolysis.
These events include the partial breakdown of com-
plex yolk lipoprotein precursors (e.g., vitellogenin)
into yolk storage proteins, the proteolytic rupture of
follicles during ovulation, and the subsequent hydro-
lysis of yolk storage proteins that is required to generate
metabolic substrate for embryonic development. The
identification of rainbow trout OPI-1 and OPI-2,
collectively possessing three distinct TY domains,
suggests a mechanism to explain how the activity of
multiple related proteases may be differentially regu-
lated during vitellogenic oocyte development. This
proposedmechanism is supported bydata fromLenarcic
and Turk (1999), who demonstrated that the three
distinct TY domains in sea anemone equistatin exhibit
differential binding affinities and inhibitory activities
against specific cathepsins and cathepsin-like pro-
teases, despite high sequence similarities between the
domains.
The data from this study provide three lines of
evidence in support of our hypothesis that OPI-1 and
OPI-2areTYdomain inhibitors that function to regulate
yolk protease activity during vitellogenic oocyte devel-
opment. Firstly, we have demonstrated the onset of
ovary-specific mRNA expression of both genes at the
onset of vitellogenin uptake in rainbow trout. Secondly,
we have shown that the proteins encoded by these
transcripts are specifically localized to defined vesicles
in the cortical ooplasm of vitellogenic oocytes. This
region of the oocyte has previously been confirmed as
the location of vitellogenin processing in avian (Ito et al.,
2003), amphibian (Wall and Patel, 1987), and piscine
species (Sire et al., 1994). Thirdly, we have demon-
strated a significant decline in mRNA expression of
OPI-1 in atretic oocytes, relative to healthy vitellogenic
oocytes. These data are consistent with our hypothesis,
and are concordant with data from earlier studies
demonstrating increased cathepsin-like protease activ-
ity in degenerating oocytes (Kestemont et al., 1999;
Wood and Van Der Kraak, 2003). We suggest that
decreased expression of TY domain protease inhibitors
at the onset of atresia would facilitate the proteolytic
degradation and resorption of yolk proteins, events
which are strongly associated with atresia in oviparous
vertebrates (Saidapur, 1978).
The expression pattern of rainbow trout OPI-1 differs
somewhat from the reported expression pattern of the
brook trout homolog (OCPI). Bobe and Goetz (2001)
detected brook trout OCPI mRNA and protein in what
were described as previtellogenic follicles, whereas we
were unable to detect OPI-1 expression in the previtel-
logenic ovary, using both immunocytochemistry and
the more sensitive RT-PCR technique. One plausible
explanation for these divergent observations relates
to the specific stages of ovarian development of fish used
in each study. In sexually mature female salmonids,
there are typically two cohorts of follicles present in the
ovary: one cohort consists of actively growing follicles
recruited for growth and maturation in the current
season, while the second cohort consists of quiescent
(non-growing) primary follicles. The latter population
remains in an arrested state until recruitment to the
vitellogenic growth phase, following ovulation of the
mature cohort. Bobe and Goetz (2001) restricted their
examination of OCPI expression to periovulatory
and postovulatory ovaries. Thus the ‘‘previtellogenic’’
follicles examined in that study had likely been
recruited to the next season’s cohort of growing follicles,
in which case vitellogenesis would likely have com-
menced. By contrast, the previtellogenic follicles exam-
ined in our RT-PCR analyses were from pre-pubertal
fish, allowing us to confirm that vitellogenesis had not
yet begun.
The fortuitous identification of OPI-2 using primers
designed to amplify OPI-1 was the result of sequence
similarities between the two cDNAs. Sequence com-
parisons of OPI-1 and OPI-2 cDNAs, however, indicate
that these transcripts are not splice variants of a single
gene, but rather represent transcription products
derived from separate genes. We have hypothesized
that these genes are paralogous, though it is unclear
at this time which was the original duplicated gene.
Sequence comparisons revealed greater similarity
between the TY domain of OPI-1 and the first TY
domain of OPI-2 (Fig. 3b), but these data alone cannot
resolve the origin of these paralogs. It also remains
unknown if this putative duplication occurred within
the species lineage, or whether other species possess an
ortholog to OPI-2; to date, none has been identified.
Our RT-PCR results demonstrating mRNA expres-
sion of OPI-1, but not OPI-2, at some stages of devel-
opment were likely the result of preferential PCR
amplification of the shorter (OPI-1) transcript, as our
RACE-PCR results confirmed that OPI-2 mRNA is
expressed throughout the vitellogenic phase of oocyte
growth. In fact, the Western immunoblot results sug-
gest that OPI-2 protein may be more abundantly
expressed than OPI-1 protein in vitellogenic oocytes.
Alternatively, the stronger immunogenic signal for
OPI-2 may simply represent greater crossreactivity of
the antiserum with the repetitive domains of OPI-2.
212 A.W. WOOD ET AL.
In summary, we have identified two putative TY
domain inhibitors in rainbow trout ovary whose expres-
sion patterns are strongly associated with the vitello-
genic phase of oocyte growth. This is the first study
to demonstrate expression of multiple TY domain
inhibitors in the developing teleost ovary, and the first
to demonstrate their expression at multiple stages of
ovarian development. Messenger RNA expression of
both genes was detected in ovarian tissues throughout
the vitellogenic phase, but was significantly reduced in
degenerating (atretic) oocytes. The proteins encoded by
these transcripts are localized to the cortical ooplasm of
vitellogenic oocytes, in direct association with sites of
vitellogenin processing. The identification of these
genes provides new evidence for the involvement of
multiple factors in regulating yolk processing during
vitellogenesis in teleosts.
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